You saw the ad. “Tirzepatide for $99 a month.” Maybe it was a scroll-stopping Instagram post, maybe a Google search ad, maybe a flyer taped to a gym mirror. And your gut said: that seems too low.
You're right to check. Tirzepatide is a real, effective medication, and it genuinely doesn't cost $99 a month almost anywhere once you add up what the average patient actually pays. That doesn't automatically mean the ad is fraudulent — but it does mean the $99 figure is very likely describing something narrower than “tirzepatide, every dose, every month, nothing else added.” This post walks through exactly how a $99 headline usually gets built, what the real market range looks like in 2026, and the specific questions that will tell you — in under a minute — what you're actually about to pay.
The 6 Common Mechanics Behind a $99/mo Teaser Price
None of the six patterns below are illegal, and none are unique to one company — they show up across subscription-based healthcare, streaming, gyms, and software alike. The reason they matter here is that GLP-1 medications involve dose titration and ongoing costs, which makes the gap between the teaser price and the real price unusually wide. Here's what a $99/mo figure is most commonly built from.
1. Starter-Dose-Only Pricing
Tirzepatide is typically prescribed starting at a low 2.5mg weekly dose, which is titrated upward over several months to a therapeutic range of 7.5–15mg. A $99 price is sometimes quoted specifically for that lowest starter dose. Once a clinician increases the dose — which is the normal, expected path of treatment — the price increases too, often substantially. The $99 figure was never meant to describe the dose most patients end up on.
2. First-Month-Only Promo That Renews at 2–3x
A promotional first-month rate is a common acquisition tactic: get the customer in the door at a low price, then renew automatically at the standard rate. It's not inherently deceptive if it's disclosed clearly — but the disclosure is often in fine print below the fold, and the auto-renewal at 2 to 3 times the advertised price is the part that catches people off guard in month two.
3. Membership or Platform Fee Added on Top
Some programs quote the medication price separately from a recurring membership or platform-access fee. The $99 may accurately describe the medication line item while a $49–$149 monthly membership fee is billed alongside it. Add the two together and the real monthly total is often two to three times the headline number.
4. Medication Charged Separately From the “Program” Fee
Related to the above, but distinct: some ads describe $99 as the cost of the program — consultations, check-ins, platform access — while the medication itself is billed as a separate line item once you're through onboarding. A patient reading “$99” reasonably assumes that figure includes the drug. It sometimes doesn't.
5. Long Commitment Contracts With Early-Exit Penalties
The lowest advertised rate is frequently gated behind a 6- or 12-month prepaid or auto-billed commitment. If you stop early — for any reason, including side effects or a clinician's recommendation — some programs don't refund the remaining months. The $99 rate is real for the person who stays the full term; it's a different, more expensive number for anyone who needs to exit early.
6. Dose-Based Price Escalation as You Titrate Up
Even outside of a strict “starter dose only” structure, some programs use a tiered price ladder that rises at each dose increase. Since tirzepatide is almost always titrated over the first several months of treatment, a patient can expect the monthly price to climb multiple times in year one under this structure, even without any promo period ending.
None of this means the ad is fake. It usually means the $99 figure is accurate for a specific, narrow scenario — the lowest dose, the first month, or the medication alone — and the job in front of you is to find out which one before you hand over a card number.
The Real Math: What Tirzepatide Actually Costs in 2026
Once you look past teaser pricing and add up what patients actually pay across a full month at a therapeutic dose, compounded tirzepatide telehealth in 2026 realistically lands in a range of roughly $232 to $449 per month, depending on the provider's structure and whether a membership fee is layered on top of the medication cost.
- SkinnyVIP: $695 for a 3-month plan (about $232/month effective), or $350 for a single month — any dose, no separate membership fee.
- Mochi Health: approximately $278/month once its recurring membership fee is combined with the medication cost.
- SkinnyRx: approximately $299/month for compounded tirzepatide.
- Henry Meds: approximately $449/month for injectable tirzepatide on an ongoing basis.
For comparison, brand-name Zepbound without insurance coverage runs $1,100 or more per month at list price, which is one reason compounded and telehealth-based options attract so much attention — and why a $99 teaser price is such an effective hook. The gap between $99 and the real market floor of roughly $232 is exactly the gap that starter-dose pricing, promo periods, and membership fees are built to fill.
For a full breakdown of how each of these providers structures its pricing — including dose tiers, contract terms, and what's actually included — see our full 2026 compounded tirzepatide pricing comparison.